Ablation of CaMKIIδ oxidation by CRISPR-Cas9 base editing as a therapy for cardiac disease

Area of Science:

• Cardiovascular biology
• Gene editing technologies
• Molecular cardiology

Background:

• CRISPR-Cas9 gene editing shows promise for treating genetic disorders.
• Current gene editing therapies target limited patient groups with specific mutations.
• CaMKIIδ is a key protein implicated in driving cardiac disease progression.

Purpose of the Study:

• To develop a cardioprotective strategy using base editing for a broad range of heart disease patients.
• To investigate the efficacy of ablating oxidative activation sites in the CaMKIIδ gene.
• To assess the protective effects of CaMKIIδ gene editing against ischemia/reperfusion injury.

Main Methods:

• Utilized base editing to modify the CaMKIIδ gene, specifically targeting oxidative activation sites.
• Employed human induced pluripotent stem cell-derived cardiomyocytes for in vitro studies.
• Conducted in vivo experiments using a mouse model subjected to ischemia/reperfusion injury.

Main Results:

• CaMKIIδ gene editing in human cardiomyocytes prevented damage from ischemia/reperfusion injury.
• Editing the CaMKIIδ gene to remove oxidation-sensitive methionine residues conferred protection.
• In mice, CaMKIIδ gene editing improved cardiac function recovery following ischemia/reperfusion.

Conclusions:

• CaMKIIδ gene editing represents a potential therapeutic strategy for heart disease.
• This approach may offer a permanent and advanced solution for treating a wide spectrum of cardiac conditions.
• Targeting CaMKIIδ's oxidative activation sites provides a novel pathway for cardioprotection.